Teaching patients how to look their best. Please join us for our next meeting.
Click here for FAQs and other useful information on all types of cancer and treatment options.
For patients dealing with their cancer experience, the decision to take part in a clinical trial is very personal. In making treatment decisions, many medical professionals believe patients have not weighed all their options unless they consider participating in a clinical trial. Treatment options provided by clinical trials are sometimes unavailable any other way.
The Family Cancer Center strongly believes it is essential that all its patients make fully informed decisions regarding their cancer care. Often, some of the best options are clinical trials. When a patient is invited to consider participation in a research study, it is important that he or she understand the purpose, risks, and benefits. This process is known as informed consent. The patient’s physician and research nurses will guide the patient through this process. As a community-based cancer center since 1997, our core commitment in offering complete care includes clinical trials for most cancers among our six research offices and nine physicians. To view the opportunities currently available at the Family Cancer Center, please select from the list of related organs below:
Phase II Study of Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER2-Negative Breast Cancer (Sarah Cannon Research Institute BRE 133)
A Phase II Trial of Panitumumab, Gemcitabine, and Carboplatin in Triple-Negative Metastatic Breast Cancer (Sarah Cannon Research Institute BRE 126)
A Randomized Trial of Ixempra ™ vs. Taxol in Adjuvant Therapy of Triple Negative Breast Cancer (Sarah Cannon Research Institute BRE 145).
A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients with HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer (Imclone 0606)
A Phase III, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2 Positive Locally Recurrent or Metastatic Breast Cancer (Wyeth 3005)
By Dr. Aleksandar Jankov
I was about to slide my hand into the sterile glove when my patient, George, interrupted the quiet business of the procedure room.